Navigation Links
Luminol-enhanced Assay for Superoxide Anion (O2 face="Symbol" ,,,)

but also requires a large number of cells (106) per assay. The third method, luminol-mediated chemiluminescence, is the most sensitive method of all; accurate readings can extend three orders of magnitude over the signal range.

The Luminol Chemiluminescence Reaction

The chain of events for the luminol chemiluminescence (CL) assay is believed to involve cell surface receptors, such as those binding to complex immunoglobulin G (Fc receptors) or bacterial formylated peptides (f-met-leu-phe receptors), which are stimulated by their specific agonists. The activated receptor triggers the production or activation of NADPH oxidase, leading to the production of superoxide anion. Superoxide anion is subsequently released into the extracellular environment where it can oxidize luminol and available lipids and proteins. This oxidation results in chemiluminescence, a release of photons (light), which can be measured by a luminometer. Figure 1 illustrates Stratagenes enhanced chemiluminescent procedure for measuring superoxide anion.

When concentrations of superoxide anion are very low, assay sensitivity may need to be enhanced. Some enhancement reagents, such as iodophenol, are phenolic-based compounds. Unfortunately, such enhancers are toxic to live cells and denaturing to some components of subcellular systems; hence, they cannot be used for in situ assays. However, Stratagenes specific enhancement reagent increases photon output but is noncytotoxic and does not denature cellular components used in assaying live cell activity.

Assay for Superoxide Anions in U-937 cells

Cell cultures were provided with an analyte suspected of being able to generate superoxide anion; luminol and enhancement reagents were then added. Superoxide anion generated was measured as a result of luminol oxidation.

As a model, U-937 cells (monocytic-like, histocytic human lymphoma) were cultured in RPMI supplemen
'"/>

Source:


Page: All 1 2 3 4 5

Related biology technology :

1. A Positive Selection Assay for Mutation Analysis in Big Blue Animals
2. Organize Your Data from the Big Blue Mutation Assay
3. Fluorescence-Based Single-Tube Assays to Rapidly Detect Human Gene Mutations
4. RNase Protection Assay (RPA) Using DIG-Labeled RNA Probes
5. measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay
6. Matched siRNAs and Assays: Ambion + Applied Biosystems = RNAi Success
7. Using Validated siRNAs in Functional Genomic Assays
8. Nuclease Protection Assays: The Basics
9. RNArticles: RNA Amplification Used to Develop a New In Vitro HCMV Assay
10. Detection of Phosphorylated and Total ERK and p38 MAPK by Bio-Plex Assay, ELISA, and Western Blotting, Rev A
11. Correlation of Bio-Plex Suspension Array Reader Validation With Multiplex Cytokine Assay Performance, Rev A
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Luminol enhanced Assay for Superoxide Anion face Symbol

Other Biology Technology:ROBODOC(R) Emerges as a Curexo Technology Company at Upcoming Orthopaedic Surgeons Conference in San Francisco 2MBF Healthcare Acquisition Corp. and Critical Homecare Solutions Holdings, Inc. to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference 2MBF Healthcare Acquisition Corp. and Critical Homecare Solutions Holdings, Inc. to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference 3US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 2US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 3US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 4US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 5US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 6US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 7US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 8US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 9US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 10US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 11US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 12US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 13US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 14US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 15US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 16US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 17US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 18US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 19US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 20US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 21US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 22US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 23US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 24US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 25US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 26